Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Main objective of this study is to describe the evolution of infusion settings (base, high and low infusion rates) of foslevodopa/foscarbidopa subcutaneous infusion (LDp/CDp) at different timepoints in the treatment of advanced Parkinson's disease (aPD) as captured in ONE-CRM.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants with Parkinson's Disease | Advanced Parkinson Disease Patients treated with foslevodopa/foscarbidopa. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Mean Base Infusion Rate | Mean base infusion rate (ml/hour) will be assessed | Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification). |
| Mean Low Infusion Rate | Mean low infusion rate (ml/hour) will be assessed | Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification). |
| Mean High Infusion Rate | Mean high infusion rate (ml/hour) will be assessed | Through end of optimization period (defined as no additional dose modification for at least 15 days since the last dose modification). |
Not provided
Not provided
Inclusion Criteria:
- Diagnosed with levodopa-responsive idiopathic Parkinson's Disease prescribed on LDp/CDp CSCI in routine clinical practice who have consented to be enrolled in the AbbVie Patient Support Program.
Not provided
Not provided
Not provided
Advanced Parkinson Disease Patients treated with foslevodopa/foscarbidopa.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| ABBVIE CALL CENTER | Contact | 844-663-3742 | abbvieclinicaltrials@abbvie.com |
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medizinische Universitaet Graz /ID# 278569 | Not yet recruiting | Graz | Styria | 8010 | Austria | |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42322391 | Derived | Warnecke T, Van der Plas AA, Schwingenschuh P, Johansson A, Simu M, O'Meara M, Gupta R, Fritz B, Bergmann L, Parra JC, Sudmeyer M. Observational Retrospective Cohort of Patient Support Program Data on Practical Experiences of Treatment with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: The ORCHESTRA Study. Neurol Ther. 2026 Jun 20. doi: 10.1007/s40120-026-00978-0. Online ahead of print. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Medisch Spectrum Twente /ID# 276695 |
| Recruiting |
| Enschede |
| Overijssel |
| 7512 KZ |
| Netherlands |
| Universitatea De Medicină Și Farmacie Victor Babeș /ID# 276720 | Recruiting | Timișoara | Timiș County | 300041 | Romania |
| Karolinska University Hospital Solna /ID# 277116 | Recruiting | Solna | Stockholm County | 171 64 | Sweden |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |